GlassScriptPhysician profile
Matthew J Kettman
NPI 1245218882
$2,238.26
in general payments reported to CMS, 2019-2025
28 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.58 · 2020: $519 · 2021: $350 · 2022: $355 · 2023: $431 · 2024: $288 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $740.39 | 2021-2025 | |
| Wardlow Enterprises | $373.77 | 2020 | |
| Lilly USA, LLC | $122.03 | 2019-2025 | Kisunla, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $99.30 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $92.49 | 2021 | |
| Arthrex, INC. | $90.05 | 2020 | |
| Novo Nordisk INC | $81.98 | 2021-2025 | Wegovy |
| Allergan, INC. | $77.66 | 2019-2021 | |
| Axsome Therapeutics, INC. | $71.92 | 2023-2024 | Auvelity |
| Corium, LLC | $44.84 | 2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $43.91 | 2022-2023 | |
| Pfizer INC. | $39.18 | 2024-2025 | |
| Alkermes, INC. | $38.76 | 2022-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.98 | 2022-2025 | Caplyta |
| Revance Therapeutics, INC. | $30.40 | 2025 | Daxxify |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prism Medical | $28.98 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $26.09 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $23.87 | 2022 | |
| Astellas Pharma US INC | $22.19 | 2025 | Veozah |
| Amgen INC. | $20.64 | 2019 | |
| Lundbeck LLC | $20.15 | 2022 | |
| Abbott Laboratories | $20.00 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $17.33 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.56 | 2023 | Xifaxan, Trulance |
| Galderma Laboratories, L.P. | $15.46 | 2025 | |
| Idorsia Pharmaceuticals US INC | $15.42 | 2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $15.18 | 2024 | Eliquis |
| Harmony Biosciences LLC | $13.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Kettman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.